Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study

Breast Cancer Research and Treatment

Volumn 148, Issue 2, 2014, Pages 345-353

  Jacob, J ^a   Belin, L ^a   Pierga, J Y ^a   Gobillion, A ^a   Vincent Salomon, A ^a   Dendale, R ^a   Beuzeboc, P ^a   Campana, F ^a   Fourquet, A ^a   Kirova, Y M ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Concurrent treatment; Radiotherapy; Toxicity; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EPITHELITIS; ESOPHAGITIS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INTENSITY MODULATED RADIATION THERAPY; ISCHEMIC CARDIOMYOPATHY; LOADING DRUG DOSE; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; ONSET AGE; OVERALL SURVIVAL; PERICARDITIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SINUS TACHYCARDIA; SKIN MANIFESTATION; TREATMENT DURATION; VEIN THROMBOSIS; ADJUVANT THERAPY; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMORADIOTHERAPY; ENZYME IMMUNOASSAY; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRASTUZUMAB;

EID: 84911961162     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3166-5     Document Type: Article

References (41)

1. Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor-2 positive breast cancer. J Clin Oncol 27:5838–5847
2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
3. Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691
4. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672
6. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684
7. Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomised trials. Lancet 366:2087–2106
8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, Mc Gale P et al (2011) Effect of radiotherapy after breast-conserving surgery on 10 year recurrence and 15 year breast cancer death: meta-analysis on individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716
9. Pietras RJ, Poen JC, Gallardo D et al (1999) Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347–1355
10. Belkacémi Y, Gligorov J, Ozsahin M et al (2008) Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 19:1110–1116
11. Shaffer R, Tyldesley S, Rolles M et al (2009) Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 90:122–126
12. Bellon JR, Gover MT, Burstein HJ et al (2005) Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer. Int J Radiat Oncol Biol Phys 63(Suppl 1):S55–S56
13. Meattini I, Cecchini S, Muntoni C et al (2014) Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. Med Oncol 31:891
14. Caussa L, Kirova YM, Gault N et al (2011) The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study. Eur J Cancer 47:65–73
15. Raben A, Sammons S, Hanlon A et al (2006) Comparison of acute breast and chest wall toxicity in women treated with external beam irradiation with and without concurrent herceptin in a community cancer center. Int J Radiat Oncol Biol Phys 66(Suppl):S541–S542
16. Horton JK, Halle J, Ferraro M et al (2010) Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 76:998–1004
17. American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New York
18. Pierga JY, Bidard FC, Mathiot C et al (2008) Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14:7004–7010
19. Bollet MA, Sigal-Zafrani B, Gambotti L et al (2006) Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. Eur J Cancer 42:2286–2295
20. Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664–5671
21. Kirova YM, Hijal T, Campana F et al (2014) Whole breast radiotherapy in the lateral decubitus position: a dosimetric and clinical solution to decrease the doses to the organs at risk (OAR). Radiother Oncol 110:477–481
22. Fournier-Bidoz N, Kirova YM, Campana F et al (2012) Simplified field-in-field technique for a large-scale implementation in breast radiation treatment. Med Dosim 2012 Summer 37:131–137
23. Kirova YM, Campana F, Fournier-Bidoz N et al (2007) Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy. Int J Radiat Oncol Biol Phys 69:1139–1144
24. Hurkmans CW, Borger JH, Bos LJ et al (2000) Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol 55:145–151
25. Kong FM, Klein EE, Bradley JD et al (2002) The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart dose for intact breast radiation. Int J Radiat Oncol Biol Phys 54:963–971
26. Halyard MY, Pisansky TM, Dueck AC et al (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III Trial N9831. J Clin Oncol 27:2638–2644
27. Belkacémi Y, Gligorov J (2010) Concurrent trastuzumab-internal mammary irradiation for HER2 positive breast cancer: “It hurts to be on the cutting edge”. Radiother Oncol 94:119–120
28. Prosnitz RG, Marks LB (2005) Radiation-induced heart disease: vigilance is still required. J Clin Oncol 23:7391–7394
29. Whelan TJ, Olivotto I, Ackerman I et al (2011) NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 29 (Suppl):abstract LBA1003
30. Poortmans P, Struikmans H, Kirkove C et al (2013) Irradiation of the internal mammary and medial supraclavicular lymph nodes in stage I to III breast cancer: 10 years results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922/10925. Eur J Cancer 49(Suppl 3):S1–S2
31. Hennequin C, Bossard N, Servagi-Vernat S et al (2013) Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys 86:860–866
32. Chang JS, Park W, Kim YB et al (2013) Long-term survival outcomes following internal mammary node irradiation in stage II–III breast cancer: results of a large retrospective study with 12 year follow-up. Int J Radiat Oncol Biol Phys 86:867–872
33. Harris EE, Correa C, Hwang WT et al (2006) Late cardiac mortality and morbidity in early stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24:4100–4106
34. Tarantini L, Cioffi G, Gori S et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18:113–119
35. Tarantini L, Gori S, Faggiano P et al (2012) Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol 23:3058–3063
36. Taylor CW, McGale P, Povall JM et al (2009) Estimating cardiac exposure from breast cancer radiotherapy in clinical practice. Int J Radiat Oncol Biol Phys 73:1061–1068
37. Bornstein BA, Chang CW, Rhodes LM et al (1990) Can simulation measurements be used to predict the irradiated lung volume in the tangential fields in patients treated for breast cancer? Int J Radiat Oncol Biol Phys 18:181–187
38. Neal AJ, Yarnold JR (1995) Estimating the volume of lung irradiated during tangential breast irradiation using the central lung distance. Br J Radiol 68:1004–1008
39. Das IJ, Cheng EC, Freedman G et al (1998) Lung and heart dose volume analyses with CT simulator in radiation treatment of breast cancer. Int J Radiat Oncol Biol Phys 42:11–19
40. Coon AB, Dickler A, Kirk MC et al (2010) Tomotherapy and multifield intensity-modulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy. Int J Radiat Oncol Biol Phys 78:104–110
41. Quinn A, Holloway L, Hardcastle N et al (2013) Normal tissue dose and second cancer risk due to megavoltage fan-beam CT, static tomotherapy and helical tomotherapy in breast radiotherapy. Radiother Oncol 108:266–268